PHILADELPHIA–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced partnerships with the Dilated Cardiomyopathy (DCM) Foundation, the Heart Failure Society of America (HFSA) and the American Association of Heart […]
Author: Ken Dropiewski
SUPIRA MEDICAL, A SHIFAMED PORTFOLIO COMPANY, CLOSES $30M IN AN OVERSUBSCRIBED SERIES C FINANCING
Company to Advance its Next Generation Percutaneous Ventricular Assist Device LOS GATOS, Calif., Feb. 28, 2022 /PRNewswire/ — Supira Medical, Inc., a Shifamed portfolio company that is focused on developing a next-generation solution for temporary mechanical circulatory support, announced today the closing of $30M in Series C financing. Led by Cormorant Asset Management and The […]
Ra Medical Systems Files 510(k) Application for the DABRA Catheter with Braided Overjacket and Six-Month Shelf Life
CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on developing its excimer laser system to treat vascular diseases, announces the filing of a 510(k) application with the U.S. Food and Drug Administration (FDA) for the company’s next-generation DABRA catheter with a braided overjacket and […]
Zio® by iRhythm Shows Significantly Higher Documentation of Atrial Fibrillation and Atrial Flutter Compared to Holter Monitors, Event Monitors
Additional clinical research shows bradyarrhythmias can be detected with 14-day cardiac monitoring through Zio XT before and after TAVR SAN FRANCISCO, Feb. 28, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, announced that the results of the KP-Rhythm2 study, titled […]
Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLX™ LAAC Device
MARLBOROUGH, Mass., Feb. 28, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced positive results from a new analysis assessing real-world outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Presented during a late-breaking trial session at the Cardiovascular Research Technologies (CRT) 2022 meeting, the SURPASS analysis included data from more […]
Semler Reports Fourth Quarter and Year-to-Date 2021 Financial Results
2021 HIGHLIGHTS compared to 2020: — Annual revenues increased by 37% — Net income increased by 23% — Cash at December 31, 2021 increased to $37.3 million from $22.1 million SANTA CLARA, Calif., Feb. 28, 2022 /PRNewswire/ — Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical […]
AbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD)
– cGVHD is a life-threatening and rare condition that currently does not have an approved treatment for children under 12 and can occur in patients after receiving peripheral blood or bone marrow stem cell transplantation – If approved, IMBRUVICA would offer pediatric and adolescent patients the first BTKi treatment option […]
The Israeli start-up CVAid raises $4 million, including investment by Philips for its AI-based platform for diagnosis of stroke
TEL AVIV, Israel, Feb. 28, 2022 /PRNewswire/ — The Israeli digital health company CVAid Medical, which has developed a platform based on artificial intelligence for diagnosing and treating cerebrovascular accidents (CVAs, or strokes), has announced the completion of capital raising from Philips together with Sanara Capital. The Israeli Rad Biomed investment fund led […]
BIOTRONIK Sets New Clinical Benchmark with Ultrathin Strut Orsiro Coronary Drug-Eluting Stent
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro’s Position as the Clinical Benchmark for DES BÜLACH, Switzerland, Feb. 28, 2022 /PRNewswire/ — BIOTRONIK is pleased to announce five-year data from the BIOFLOW-V trial, which was presented yesterday at the 2022 CRT Conference during a late-breaking clinical trial session by Dr. David […]
Humacyte Announces Publication of Positive Long-Term Follow-Up Data from Phase 2 Trial of HAV™ for Hemodialysis
— Five-year data demonstrate the potential of the Human Acellular VesselTM (HAV) to be a durable and safe option for vascular access for routine, long-term hemodialysis — — Results published in EJVES Vascular Forum — DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing […]



